Philogen S.p.A. (PHIL)’in fiyatı nedir?

Philogen S.p.A. (PHIL)’in fiyatı $27.76’dir

Philogen S.p.A. (PHIL)’in piyasa değeri nedir?

Philogen S.p.A. (PHIL)’in piyasa değeri $801.60M’dir.

Philogen S.p.A. (PHIL) Temettüler

Philogen S.p.A. is a biotechnology firm dedicated to creating therapeutic agents for cancer and persistent inflammatory conditions. Among its pipeline, Nidlegy is being developed as an intralesional therapy for localized melanoma and non-melanoma skin cancers, combining the immunocytokines L19IL2 and L19TNF. Another key product is Fibromun, a human immunomodulatory agent composed of the L19 antibody and TNF, aimed at treating soft tissue sarcoma, leiomyosarcoma, and glioma. Darleukin, also known as L19IL2, is a human immunostimulatory product that integrates the human L19 antibody with the human cytokine interleukin-2 (IL2); it is currently undergoing Phase II clinical trials for addressing non-small cell lung cancer. The company's developmental efforts also include Dodekin, a human immunostimulatory product in Phase I/II clinical trials, consisting of a vascular targeting antibody fused with interleukin-12, designed to combat advanced solid tumors. For chronic inflammation, Dekavil (F8IL10), an anti-inflammatory compound, is in Phase I clinical trials. Furthermore, Philogen is advancing diagnostic radiotracers: Onco IX (PHC-102), a 99mTc labelled small molecule, is in Phase I, intended for the non-invasive detection of solid tumors that express carbonic anhydrase IX (CAIX). Similarly, OncoFAP, another small molecule radiotracer, is also in Phase I, focusing on the non-invasive identification of various metastatic solid tumors by targeting fibroblast activation protein. Established in 1996, Philogen S.p.A. operates from its headquarters in Sovicille, Italy.

Yıl	Temettü (hisse bölünmesiyle ayarlanmış)	Değiştir
Sağlanan tarihler için yeterli veri yok.

Yıl

Temettü (hisse bölünmesiyle ayarlanmış)

Değiştir

Sağlanan tarihler için yeterli veri yok.

Yıl	Temettü	Değiştir
Sağlanan tarihler için yeterli veri yok.

Yıl

Temettü

Değiştir

Sağlanan tarihler için yeterli veri yok.

Şirket	Temettü ödemesi sayısı	Ülke
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
CSL Limited CSL.AX	64.00%	AU
Moderna, Inc. MRNA.US	0.00%	US
Lonza Group AG LONN.SW	0.00%	CH

Şirket

Temettü ödemesi sayısı

Ülke